said it has received full approval from the FDA for its drug Rebrevant plus chemotherapy as a first-line treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations. The ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations. These mutations are identified by an FDA-approved test in patients. Sunvozertinib, an irreversible EGFR ...